|apersy|

Value | Market Access | Commercialisation

The monthy 3 minutes of selected bits of news:

62 seconds on DiPAs – digital care and nursing applications are launching in Germany

Microbiome product Rebyota is now approved in the US – we are keenly watching out for access, uptake and reimbursement learnings…

AIFA reimbursement committees merge

Germany rare disease medicine Brineura to recevie highest benefit rating with 5-year follow-up data and RWE

Other recent posts: